Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Jennifer R Eads"'
Autor:
John Wright, Patrick M Forde, Robert L Ferris, Ahmad A Tarhini, Kathleen N Moore, Jennifer R Eads, Valerie Tatard-Leitman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 8 (2022)
Definitive management of locoregionally advanced solid tumors presents a major challenge and often consists of a combination of surgical, radiotherapeutic and systemic therapy approaches. Upfront surgical treatment with or without adjuvant radiothera
Externí odkaz:
https://doaj.org/article/0837f91f0af34ef39b6c5c784cd6e2a9
Autor:
Hwan Lee, Sarit T. Kipnis, Remy Niman, Sophia R. O’Brien, Jennifer R. Eads, Bryson W. Katona, Daniel A. Pryma
Publikováno v:
Cancers, Vol 16, Iss 1, p 200 (2023)
Background: Treatment of metastatic neuroendocrine tumors (NET) with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) results in favorable response only in a subset of patients. We investigated the prognostic value of quantitative pre-trea
Externí odkaz:
https://doaj.org/article/3926c418379e49cb833ab90ce34f0bc7
Autor:
William J. Chapin, Jacob E. Till, Wei-Ting Hwang, Jennifer R. Eads, Thomas B. Karasic, Peter J. O'Dwyer, Charles J. Schneider, Ursina R. Teitelbaum, Janae Romeo, Taylor A. Black, Theresa E. Christensen, Colleen Redlinger Tabery, Amanda Anderson, Megan Slade, Michael LaRiviere, Stephanie S. Yee, Kim A. Reiss, Mark H. O'Hara, Erica L. Carpenter
Publikováno v:
JCO precision oncology. 6
PURPOSE Pancreatic ductal adenocarcinoma (PDAC) is associated with a poor prognosis. Multianalyte signatures, including liquid biopsy and traditional clinical variables, have shown promise for improving prognostication in other solid tumors but have
Publikováno v:
Gastroenterology Clinics of North America. 51:625-647
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are the most common type of neuroendocrine tumors and are being increasingly identified in clinical practice. The diagnosis, staging, management, and surveillance of GEP-NETs rely heavily on end
Autor:
Stephen E. Moore, Jennifer R. Eads, Carina Mari Aparici, Hwan Lee, Ryusuke Nakamoto, Daniel A. Pryma, Austin R. Pantel
Publikováno v:
Academic Radiology. 29:1308-1316
Rationale and Objectives High-grade gastroenteropancreatic neuroendocrine neoplasms (G3 GEP-NENs) are pathologically classified into well differentiated neuroendocrine tumors (G3 NETs) and poorly differentiated neuroendocrine carcinomas (G3 NECs). Us
Autor:
Jennifer R Eads, Thorvardur R Halfdanarson, Tim Asmis, Andrew M. Bellizzi, Emily K Bergsland, Arvind Dasari, Ghassan El-Haddad, Michael Frumovittz, Joshua Meyer, Erik Mittra, Sten Myrehaug, Eric Nakakura, Nitya Raj, Heloisa P Soares, Brian Untch, Namrata Vijayvergia, Jennifer A Chan
Publikováno v:
Endocrine-Related Cancer.
High grade neuroendocrine tumors (G3 NET) and neuroendocrine carcinomas (NEC) are a rare disease entity for which there is a limited amount of prospective data available. It has also been relatively recent that a distinction has been made between G3
Publikováno v:
JCO Precision Oncology.
Autor:
Dan G. Duda, Andrew X. Zhu, Devalingam Mahalingam, Rebecca Miksad, Alok A. Khorana, Thomas A. Abrams, Gulam A. Manji, Anthony B. El-Khoueiry, Stacey Stein, Jennifer R. Eads, Michael H. Kagey, Michael Schrag, Cynthia Sirard, Lipika Goyal
Purpose:Dickkopf-1 (DKK1) modulates Wnt signaling, promoting tumor growth, metastasis, and immunosuppression. High DKK1 expression has been detected in various tumor types—including biliary tract cancer (BTC)—and is associated with poor prognosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3acc2e0adf4f209458f9bd53a8d231f5
https://doi.org/10.1158/1078-0432.c.6529550.v1
https://doi.org/10.1158/1078-0432.c.6529550.v1
Autor:
Dan G. Duda, Andrew X. Zhu, Devalingam Mahalingam, Rebecca Miksad, Alok A. Khorana, Thomas A. Abrams, Gulam A. Manji, Anthony B. El-Khoueiry, Stacey Stein, Jennifer R. Eads, Michael H. Kagey, Michael Schrag, Cynthia Sirard, Lipika Goyal
Text and Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::189c3a90ac5930ea842b4b08064234ff
https://doi.org/10.1158/1078-0432.22476995.v1
https://doi.org/10.1158/1078-0432.22476995.v1
Autor:
Zhenghe Wang, Jennifer R. Eads, Neal J. Meropol, Sanford D. Markowitz, David L. Bajor, Yan Xu, Martina Veigl, Shaveta Vinayak, Smitha S. Krishnamurthi, Joel Saltzman, Jill S. Barnholtz-Sloan, Ronald A. Conlon, Gino Cioffi, Yujun Hao, Janet M. Wang, Zhanwen Du, Shashank Gorityala, J. Eva Selfridge, Yicheng Chen, Xiujing Feng, Yiqing Zhao
Supplementary Figures 1-6 and Tables 1-3. Figure S1. PIK3CA mutant cells are more sensitive to a glutaminase inhibitor CB-839 than their WT counterparts. Figure S2. CB-839 enhances 5-FU tumor inhibitory effect in PIK3CA mutant CRC. Figure S3. Genes a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00979391b3ffe7f859a4ff0835457ca3
https://doi.org/10.1158/0008-5472.22426516.v1
https://doi.org/10.1158/0008-5472.22426516.v1